Gapping up
In reaction to strong earnings/guidance: TTM +12.8%, NPD +11.5%, AMSC +5.3%, FRO +3.5%, LPG +3.2%, YY +2.3%
M&A news: CPXX +71.4% (to be acquired by Jazz Pharmaceuticals (JAZZ) for $30.25 per share in cash), WR +9.1% (to be acquired by Great Plains Energy (GXP) for $51/share in cash & $9/share in Great Plains Energy common stock), SANW +4.5% (announces acquisition of SV Genetics for $1 mln in cash and $1 mln in stock), DANG +4.1% (to be acquired by its parent co in a going-private transaction for cash consideration of $6.70/ADR), MON +1% (Bayer (BAYRY) might increase bid for MON, according to Sunday Times)
Other news: CBAY +13.2% (announces top line efficacy and safety data from its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC); study stopped early after meeting its objective), SODA +10.1% (announced the release of its new home beer system), CBYL +8.5% (continued volatility in pre-mkt trading), ICPT +6.5% (receives accelerated approval grant from FDA for Ocaliva), NVCR +6.2% (receives IDE approval to initiate METIS trial), FOLD +5.5% (announces European Commission approval for Galafold (Migalastat) in patients with Fabry Disease in European Union), MT +4.4% (CLF enters into a long-term agreement with ArcelorMittal), LC +3.1% (continued momentum from last week), TNXP +3.1% (will present 'positive' results from its Phase 2 AtEase Study of TNX-102 SL on May 31 and June 1 at the 2016 ASCO), LXRX +3.1% ( The FDA has accepted for filing the New Drug Application for telotristat etiprate), BRCD +2.4% (to replace MDC Holdings (MDC) in the S&P MidCap 400), JD +1.9% (Shanghai +3% overnight), ACAD +1.9% (announces that NUPLAZID is now available for prescription in the US), PRGO +1.7% (receives FDA approval for launch of generic equivalent to Flonase), ARIA +1.7% (initiates Phase 1/2 clinical trial of AP32788), ODP +1.7% (announces $100 mln stock repurchase program), VRX +1.1% (continued momentum from last week), BUD +1.1% (Barron's profiles positive views on BUD)
Analyst comments: MU +4.2% (upgraded to Outperform from Neutral at Robert W. Baird), DE +2% (upgraded to Buy from Neutral at UBS), MRO +1.4% (upgraded to Overweight from Neutral at Piper Jaffray)